Retatrutide Dropout Rates: How Many Quit and Why
Between 6-16% of Phase 2 participants discontinued due to side effects. Here is what that tells us about retatrutide's real-world tolerability.
Retatrutide dropout rates from the Phase 2 clinical trial (Jastreboff et al., NEJM 2023) tell an important story about the drug's tolerability. While the headline weight loss of 24.2% is extraordinary, a medication only works if patients can stick with it. Discontinuation rates of 6-16% across dose groups — while slightly higher than semaglutide or tirzepatide — still mean that the vast majority of participants (84-94%) completed treatment. Understanding who quit and why helps set realistic expectations.
Phase 2 Data
Dropout data is from the Phase 2 trial. Phase 3 trials with optimized dosing may show different completion rates. Retatrutide is not FDA-approved.
Dropout Rates by Dose Group
Discontinuation Due to Adverse Events
| Dose Group | Discontinued (%) | Completed (%) | Avg Weight Loss |
|---|---|---|---|
| Placebo | ~3% | ~97% | -2.1% |
| 1 mg | ~6% | ~94% | -8.7% |
| 4 mg | ~8% | ~92% | -17.1% |
| 8 mg | ~10% | ~90% | -22.8% |
| 12 mg | ~10-16% | ~84-90% | -24.2% |
Approximate rates. The 12 mg range reflects different escalation schedules within the dose group.
Why People Quit
The primary reasons for discontinuation mirror the side effect profile:
- Nausea (most common): Persistent nausea during dose escalation was the leading cause of dropout. While most nausea is mild-moderate and transient, some participants found it intolerable.
- Vomiting: More severe than nausea, vomiting was the second most common reason.
- Diarrhea: Persistent diarrhea led some participants to discontinue.
- Multiple GI symptoms: Participants experiencing several GI symptoms simultaneously were more likely to quit than those with a single symptom.
- Non-AE reasons: A small number discontinued for reasons unrelated to side effects (personal choice, moved, lost to follow-up).
When People Quit
Dropout timing is informative:
- Most dropouts occurred during dose escalation: The period when doses increase is when GI side effects peak. Once patients reach their target dose and stabilize, dropout rates decrease significantly.
- First 8-12 weeks: The highest risk period. Patients who make it past the initial escalation phase are much more likely to complete treatment.
- Steady state: Once at a stable dose for several weeks, side effects typically diminish and tolerability improves.
How This Compares to Other Drugs
| Drug | Discontinuation Rate | Avg Weight Loss |
|---|---|---|
| Semaglutide 2.4 mg | ~7% | -14.9% |
| Tirzepatide 15 mg | ~7% | -22.5% |
| Retatrutide 12 mg | ~10-16% | -24.2% |
The pattern is clear: more potent drugs with more receptor targets tend to have slightly higher discontinuation rates. But the magnitude of additional weight loss (24% vs 15-22%) far outweighs the modest increase in dropout risk. And for the 84-90% who complete treatment, the results are unparalleled.
Expected Phase 3 Improvements
Phase 3 trials incorporate lessons from Phase 2 to improve tolerability:
- Slower dose escalation: More gradual increases allow the body more time to adjust
- Optimized escalation intervals: Longer periods at each dose step before increasing
- Refined dose selection: The most effective dose with acceptable tolerability may differ from Phase 2
- Better patient education: Setting expectations about transient GI side effects helps patients persist through the adjustment period
Well-Tolerated Options Available Now
Current GLP-1 medications have excellent completion rates and are available through TRIMI:
- Compounded semaglutide: $99/month
- Compounded tirzepatide: $125/month
Learn more about how to get started.
Medical Disclaimer
Retatrutide is investigational and not FDA-approved. Dropout data from Phase 2 (Jastreboff et al., NEJM 2023). Phase 3 dropout rates may differ. If you experience intolerable side effects on any medication, consult your healthcare provider before discontinuing.
Well-Tolerated Treatment Available Now
High completion rates, proven results. Semaglutide from $99/mo, tirzepatide from $125/mo.
Get Started TodayMore on triumph trials
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).